B
BioXcel Therapeutics D
D
BTAI
1.54000
USD
-0.22
(-12.50%)
مغلق
حجم التداول
4,613
الربح لكل سهم
-4
العائد الربحي
-
P/E
-0
حجم السوق
9,326,311
الأخبار المقالات
العنوان: BioXcel Therapeutics Inc
القطاع: Healthcare
الصناعة: Biotechnology
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology.The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.